Search / Trial NCT00002062

Open-Label "Compassionate" Use Study of Spiramycin for the Treatment of Diarrhea Due to Chronic Cryptosporidiosis in Immunocompromised Patients

Launched by RHONE-POULENC RORER · Aug 30, 2001

Trial Information

Current as of December 26, 2024

Completed

Keywords

Spiramycin Aids Related Opportunistic Infections Immune Tolerance Cryptosporidiosis Diarrhea Drugs, Investigational Acquired Immunodeficiency Syndrome

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with known sensitivity to macrolide antibiotics are excluded. Consideration must be given to the fact that spiramycin is a macrolide antibiotic and, therefore, may have the potential to induce hepatotoxicity.
  • Patients with a compromised immune system may have hepatic abnormalities or even hepatitis. If the benefit-to-risk ratio does not favor the use of spiramycin, the patients must be excluded from the study.
  • Concurrent Medication:
  • Excluded:
  • Other investigational drugs.
  • Patients with known sensitivity to macrolide antibiotics are excluded. Consideration must be given to the fact that spiramycin is a macrolide antibiotic and, therefore, may have the potential to induce hepatotoxicity.
  • Patients with a compromised immune system may have hepatic abnormalities or even hepatitis. If the benefit-to-risk ratio does not favor the use of spiramycin, the patients must be excluded from the study.
  • Prior Medication:
  • Excluded within 7 days of study entry:
  • Other investigational drugs.
  • Diagnosis of chronic diarrhea due to cryptosporidiosis and a compromised immune system but not limited to patients with AIDS.
  • Patients receiving chemotherapy for a malignancy.
  • Patients who are iatrogenically immune-suppressed following organ transplantation.

About Rhone Poulenc Rorer

Rhone-Poulenc Rorer, a prominent global pharmaceutical company, specializes in the research, development, and commercialization of innovative therapeutic solutions across various medical fields. With a strong commitment to advancing healthcare, the company focuses on delivering high-quality pharmaceuticals that address unmet medical needs, emphasizing rigorous clinical trials and regulatory compliance. Leveraging its extensive expertise in drug development and a collaborative approach, Rhone-Poulenc Rorer aims to enhance patient outcomes and contribute to the overall well-being of communities worldwide.

Locations

Horsham, Pennsylvania, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials